Welcome to MissouriLifeScience.com
MissouriLifeScience.com is part of a specialized network of state based biotechnology, medical device,
and life science sites that includes more than 3,500 biotechnology, medical device, pharmaceutical companies,
non-profit research institutions, universities and supporting service sector companies across the U.S.
This network addresses the growing informational and service needs of companies, patients, educators and others in
their respective states while providing clients the opportunity to cost effectively
advertise their job openings, events, facility availability and other services at the state level,
regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting
services.
More...
|
|
Learn About Missouri's BioHistory
Why is there a biotechnology industry in Missouri? Will the industry continue
to grow in Missouri? What do other states have? Each state has a unique story
that explains why a given industry has developed in a specific region and not in others.
Through Missouri BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industries in the state of Missouri.
More MO BioHistory...
|
|
|
Local News...
Free News Release Posting & Archiving Service
- Lilly completes final phase of its Indianapolis Biotechnology Complex Eli Lilly and Company announced completion of the final phase of its $1 billion effort to further strengthen the company's biotechnology research and development capabilities.
Eli Lilly and Company May 12, 2008
- NeoPharm announces first quarter 2008 financial results NeoPharm announced its first quarter 2008 financial results. For the first quarter ended March 31, 2008, NeoPharm reported a net loss of $1.5 million, or ($0.05) per basic and diluted share, as compared to a net loss of $5.5 million, or ($0.19) per share, for the same period last year.
NeoPharm, Inc. May 12, 2008
- Stereotaxis' market leadership highlighted at Heart Rhythm 2008 Stereotaxis announced that its participation at Heart Rhythm 2008 reflects the broad market leadership it has achieved as the only provider of fully automated, remote navigation technology for cardiac ablation.
Stereotaxis, Inc. May 09, 2008
- Spectrum announces sale of injectable generic drugs to Sagent Spectrum Pharmaceuticals announced that it has sold its abbreviated new drug applications for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Sagent Pharmaceuticals.
Spectrum Pharmaceuticals, Inc. May 09, 2008
- Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
Bayer May 08, 2008
More... | Submit News Release | National News
|
New Job Postings...
Free Job Posting Trial Offer
More... |
Job Advertising...
| About Job Postings...
|
Upcoming Events...
Free Event Posting Service
More... |
Submit Event |
Event Advertising...
|
|